Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q969J5

UPID:
I22R2_HUMAN

ALTERNATIVE NAMES:
Cytokine receptor class-II member 10; Cytokine receptor family 2 member 10; Cytokine receptor family type 2, soluble 1; Interleukin-22-binding protein; ZcytoR16

ALTERNATIVE UPACC:
Q969J5; Q08AH7; Q6UWM1; Q96A41; Q96QR0

BACKGROUND:
The Interleukin-22 receptor subunit alpha-2, also referred to as Cytokine receptor family 2 member 10 or ZcytoR16, is integral to immune regulation and reproductive success. It serves as an antagonist to IL22 by preventing its interaction with the IL-22R complex, thus inhibiting IL22's activity. This action is vital for controlling inflammatory responses. Additionally, its role in pregnancy underscores its importance in reproductive biology.

THERAPEUTIC SIGNIFICANCE:
The exploration of Interleukin-22 receptor subunit alpha-2's functions offers promising pathways for developing new treatments. Its dual role in inflammation and pregnancy provides a unique opportunity for therapeutic intervention in diseases related to immune dysregulation and reproductive health.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.